Antisoma Share Discussion Threads

[dasv] 18/2/2008 10:02

1Leigh - I think we might as well re-use this thread unless anyone has any objections...

[1leigh] 17/2/2008 22:29

or go back to the old one?

[dasv] 16/2/2008 10:57

scruff1 - perhaps we should start a new thread...

[scruff1] 15/2/2008 19:22

I wish littlewadds would change this header. Lookin f* ridiculous now.

[upshegoes] 15/2/2008 15:24

DaveNic

Mostly about the drugs/Novartis +buy - plenty of cash and likely takeover target at current levels.

"Elger also admits that with the company's share price languishing where it is, that it is a takeover target".

[davenic] 15/2/2008 14:49

whats did it say NM.....in a summary ???

[nmknight] 15/2/2008 14:22

good post about asm in shaqres magazine this week

[zagrem] 13/2/2008 14:44

Yes sir someone read the good doctor's post and didn't believe it! l.o.l

[pegasus59] 13/2/2008 14:32

Are we expecting news???

peg

[dasv] 13/2/2008 14:25

ello ello, level 2 has just gone mental 534k vs 176k

[zagrem] 13/2/2008 11:38

Can't disagree with that. Share price has droped significantly from when i took profits, but got back in as positive outcome would have similar effect as before, negative and it could halve or more.

Pay's your money, takes your choice, but no wishful thinking will move this significantly only shorters or an RNS i.m.o.

Here till further trial results.

[the_doctor] 13/2/2008 11:22

The trial results for ASM's lead product have been mixed. Until results show otherwise, why should anyone be particularly bullish?
It significantly dampens hopes of a bid, thats for sure.

[zagrem] 13/2/2008 11:17

OXB may be subject of over-hyped bid rumours, but one month on from this article, comments still apply, particularly with ASM.

One of the analysts at Seymour Pierce has been pondering the ice-cold attitude of investors to biotech stocks in the UK. Despite some big licensing news for the likes of Renovo, Antisoma and Oxford BioMedica in '07, Zhining Xu remarks that the British biotechs have dramatically underperformed. Other analysts note that while a host of biotechs are trading at a discount, they're likely to face some strong headwinds as they go back out this year to raise more money. It could be that investors just aren't patient enough to stick with a drug developer in the long dry spells between big announcements. Only nine of the 47 biotechs on the UK index made gains last year. Big losers: Vernalis, down 90 percent, and CeNeS, down 70 percent.

Still, says Xu, companies like Renovo, Antisoma and Oxford BioMedica may not be performing well, but they are positioned for a comeback. "All three of these companies have a solid cash position and have their lead programs covered by their partners so they are in a position to push ahead with early stage drug development projects," adds Xu.

Appeared in Fierce Biotech 10th Jan.

PATIENCE if you have it and can afford it! Just got to wait for news, whether the share languishes further the real action in these markets will come with a positive or negative RNS, until then it's fodder to shorters or market sentiment!

[juju43] 12/2/2008 20:35

oxb buyout is the usual fiction to remove money from suckers

[scruff1] 12/2/2008 20:31

Like I asked first thing 'What was that all about?'. Still asking. 5% down. Why?

[1leigh] 12/2/2008 12:34

dasv - missed the oxb buyout, that's oxb and cen then in a matter of weeks.

[1leigh] 12/2/2008 12:32

Maybe someone's seen Glyn's speech and didn't like it?

[dasv] 12/2/2008 08:48

OXB buyout may help biotech sector?

[scruff1] 12/2/2008 08:03

What's that all about?

[scruff1] 08/2/2008 20:19

Dave
We can all read an RNS and we have had lots of these presentations and none have had any effect on the share price Money in the bag is all that moves the market.

[davenic] 08/2/2008 12:05

Antisoma to present at BIO CEO & Investor Conference




Antisoma to present at BIO CEO & Investor Conference
8 February 2008, London, UK: Antisoma plc (LSE: ASM; USOTC: ATSMY)
announces that its Chief Executive, Glyn Edwards, will be presenting
at the BIO CEO & Investor Conference in New York.
The presentation is scheduled for 16:15 EST (21:15 GMT) on Tuesday,
February 12th, and a webcast will be available to all on Antisoma's
website at www.antisoma.com.
For live viewing of the webcast, it is recommended that viewers log
on 15 minutes early in order to register and download any necessary
software.Enquiries:
Daniel Elger
Director of Communications
Antisoma plc
[phone]Brian Korb
The Trout Group
[phone]

[dasv] 05/2/2008 14:39

Zagrem- the real action with gold has been with the mid to large producers where the gold price directly affects their profits. They are geared plays on the gold price whereas the juniors have a lot of "proving" to do before profits can be realised.

This is not a ramp - as I believe they are currently Overvalued but look at the chart for RRS.

[zagrem] 05/2/2008 14:12

First MDX, now CEN. Bio-tech story unfolding this year. As i've been saying and picking up various articles. Sector bombed out, consolidation plays and pipelines to be beefed up in major pharma's. All healthy for ASM!

[zagrem] 01/2/2008 20:01

Dasv, give you that, my real point is that theres not many more gold stocks doing little better than bio's. MDX holders could argue the same with junior gold bull's. Gold may be hot but the shares as yet are not following suit due to investor fear i.m.o, that is no one wants to buy them either at the mo.